Pellet

SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant β-lactamase enzyme designed...

Most of the commercially available pharmaceutical products for oral administration route are marketed in the tablet dosage forms. However, compression...

Purpose Drug X is high solubility, high permeability BCS/DCS I small molecule drug. High dose and potential pediatric indication required...

The objectives of this study are the development and evaluation of modified release multi-particulate drug delivery systems containing a BCS...

Written by Dr Steve Robinson | 01-Dec-2020 Excipients from different batches or vendors may be variable in quality and it...

Objective(s): Liqui-Mass technology has shown promising advantages in terms of commercial production and formulation manipulation. This study attempts to further...

This is the 4th Webinar on Multiparticulates in our series of "Multiparticulates - Modern oral drug products for our society"....

Increasing expectations to understand material properties and process parameters impact on drug product performance resulted in increased efforts towards evaluation...

Multiple-unit pellet systems (MUPS) oer many advantages over conventional solid dosage forms both for the manufacturers and patients. Coated pellets...

As the demand for pediatric dosage forms continues to increase across the industry, there can be formulation challenges for this...